The DMKN Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-mediated gene-disrupted polyclonal population of HeLa cells, designed for loss-of-function studies targeting the DMKN locus. This product provides a heterogeneous pool of edited cells, enabling researchers to investigate dermokine-dependent phenotypes without single-cell cloning artifacts. The knockout is achieved through non-homologous end joining following Cas9-induced double-strand breaks, resulting in a mixed allelic knockout pool. Such polyclonal knockout pools are advantageous for pooled CRISPR screens and for assessing population-level responses in epithelial biology and cancer models.
The parental HeLa cell line, derived from a cervical adenocarcinoma of Henrietta Lacks, is a widely used model in biomedical research. These adherent, epithelial-like cells exhibit robust proliferation and are permissive to a variety of genetic manipulations. HeLa cells retain key characteristics of cervical cancer, including deregulated signaling pathways and genomic instability, making them a suitable host for studying genes implicated in epithelial homeostasis and carcinogenesis. Their human origin and established use in drug discovery and functional genomics further support their selection for this knockout model.
DMKN encodes dermokine, a protein that interacts with keratin intermediate filaments to orchelate epithelial differentiation and cornification. It is transcriptionally regulated by TP63 and NOTCH1, and functions upstream of terminal differentiation effectors such as KRT10, involucrin (IVL), filaggrin (FLG), and small proline-rich proteins (SPRRs). Dermokine promotes the assembly and stabilization of keratin cytoskeletal networks, facilitating the transition from proliferative to terminally differentiated keratinocytes. Inflammatory cytokines also modulate its expression, linking DMKN to immune?Cepithelial crosstalk. Disruption of this gene therefore perturbs a critical node in the epithelial differentiation program.
Knockout of DMKN in HeLa cervical cancer cells is expected to impair differentiation marker expression and alter cellular behavior, including proliferation, migration, and adhesion. Given HeLa??s origin from a malignant epithelial context, this model is particularly suited to explore how loss of dermokine influences epithelial?Cmesenchymal transition, invasion, and response to therapeutic agents. The polyclonal nature of the knockout population allows for the evaluation of heterogeneous editing outcomes, reflecting the genetic variability often observed in tumor cell populations and enhancing the translational relevance of functional studies.
Applications include quantitative RT-qPCR and western blot analysis of differentiation markers (KRT10, IVL), immunofluorescence visualization of keratin networks, cell proliferation (MTT, BrdU) and migration/invasion (Boyden chamber) assays, and apoptosis studies. This model is valuable for CRISPR screening campaigns designed to identify modulators of epithelial integrity, for dissecting Notch and TP63 signaling pathways, and for testing compounds that target cytoskeletal or differentiation programs in cervical cancer and related skin disorders such as psoriasis. For additional information or technical support, please contact Ascent Research.
